Health Care Resource Utilization of Late Premature Versus Term Infants With Bronchiolitis.


Journal

Clinical pediatrics
ISSN: 1938-2707
Titre abrégé: Clin Pediatr (Phila)
Pays: United States
ID NLM: 0372606

Informations de publication

Date de publication:
07 2020
Historique:
pubmed: 14 5 2020
medline: 29 12 2020
entrez: 14 5 2020
Statut: ppublish

Résumé

It is controversial whether it is cost-beneficial for late preterm infants to receive respiratory syncytial virus prophylaxis. This study compares community and hospital health care resource utilization (HCRU) of late premature infants (33-36 weeks gestational age) with term infants (>36 weeks gestational age) hospitalized with bronchiolitis. This was a retrospective, population-based, observational study spanning a 9-year period (2004-2012). HCRU data were obtained from the Health Maintenance Organization "Clalit" and included duration of hospitalization, physician visits, laboratory tests, and treatments. Compared with term infants, late preterm infants had significantly longer duration of hospitalization and higher admission rates to pediatric intensive care unit. They also had higher rates of mean outpatients clinic visits, total outpatient clinic and specialist visits, blood chemistry, and virology testing. HCRU of term infants with bronchiolitis was also substantial, indicating that they also can greatly benefit from respiratory syncytial virus prophylaxis. These findings can guide stakeholders in decisions concerning the prevention of bronchiolitis and will be useful in performing further cost-benefit analysis.

Identifiants

pubmed: 32400172
doi: 10.1177/0009922820920012
doi:

Substances chimiques

Antiviral Agents 0
Palivizumab DQ448MW7KS

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

778-786

Auteurs

David Greenberg (D)

Soroka University Medical Center, Beer-Sheva, Israel.
Ben-Gurion University of the Negev, Beer-Sheva, Israel.

Ron Dagan (R)

Ben-Gurion University of the Negev, Beer-Sheva, Israel.

Eilon Shany (E)

Soroka University Medical Center, Beer-Sheva, Israel.
Ben-Gurion University of the Negev, Beer-Sheva, Israel.

Shalom Ben-Shimol (S)

Soroka University Medical Center, Beer-Sheva, Israel.
Ben-Gurion University of the Negev, Beer-Sheva, Israel.

Noga Givon-Lavi (N)

Soroka University Medical Center, Beer-Sheva, Israel.
Ben-Gurion University of the Negev, Beer-Sheva, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH